NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics said Tuesday that it has raised $5.4 million in a Series A financing from Morningside Ventures.

The company plans to use the funding to develop diagnostic tests based on its RNAscope technology.

The RNAscope is a multiplex fluorescent and chromogenic in situ hybridization platform used to detect and quantify RNA biomarkers. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.